King Wealth Management Group Has $343,000 Holdings in Pfizer Inc. (NYSE:PFE)

King Wealth Management Group lowered its position in Pfizer Inc. (NYSE:PFE) by 8.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,937 shares of the biopharmaceutical company’s stock after selling 1,216 shares during the period. King Wealth Management Group’s holdings in Pfizer were worth $343,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Swiss National Bank grew its holdings in shares of Pfizer by 0.6% during the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock worth $486,762,000 after purchasing an additional 100,900 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock worth $3,766,366,000 after buying an additional 12,864,343 shares in the last quarter. Empowered Funds LLC grew its holdings in Pfizer by 80.9% during the 3rd quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company’s stock worth $14,709,000 after acquiring an additional 227,349 shares during the last quarter. KBC Group NV increased its position in Pfizer by 26.0% in the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company’s stock valued at $89,872,000 after acquiring an additional 639,985 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after acquiring an additional 1,080,822 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of several research analyst reports. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Stock Down 0.4 %

Shares of NYSE:PFE opened at $25.60 on Friday. The company has a 50 day moving average price of $26.26 and a two-hundred day moving average price of $27.17. The company has a market capitalization of $145.08 billion, a PE ratio of 18.16, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 EPS. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.